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Combining key antigens from the different stages of the P. falciparum life cycle in the con-
text of a multi-stage-specific cocktail offers a promising approach towards the development
of a malaria vaccine ideally capable of preventing initial infection, the clinical manifestation
as well as the transmission of the disease. To investigate the potential of such an approach
we combined proteins and domains (11 in total) from the pre-erythrocytic, blood and sexual
stages of P. falciparum into a cocktail of four different components recombinantly produced
in plants. After immunization of rabbits we determined the domain-specific antibody titers as
well as component-specific antibody concentrations and correlated them with stage specific
in vitro efficacy. Using purified rabbit immune IgG we observed strong inhibition in functional
in vitro assays addressing the pre-erythrocytic (up to 80%), blood (up to 90%) and sexual
parasite stages (100%). Based on the component-specific antibody concentrations we cal-
culated the IC50 values for the pre-erythrocytic stage (17–25 μg/ml), the blood stage (40–
60 μg/ml) and the sexual stage (1.75 μg/ml). While the results underline the feasibility of a
multi-stage vaccine cocktail, the analysis of component-specific efficacy indicates signifi-
cant differences in IC50 requirements for stage-specific antibody concentrations providing
valuable insights into this complex scenario and will thereby improve future approaches
towards malaria vaccine cocktail development regarding the selection of suitable antigens
and the ratios of components, to fine tune overall and stage-specific efficacy.
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Introduction
Despite years of intensive research malaria still affects millions of people worldwide and claims
more than 500,000 lives per year, predominantly in sub-Saharan Africa [1]. Many strategies have
been pursued to develop efficient vaccine formulations that prevent infection or at least the clini-
cal development of malaria, including peptides [2], non-replicating sporozoites [3], DNA vaccines
[4], vectored and prime-boost vectored vaccines [5], various formulations of recombinant pro-
teins and fusion proteins [6–9] and fusion peptides targeting different stages of the Plasmodium
falciparum life cycle [10]. Sporozoite-based approaches have the potential to induce sterile immu-
nity but manufacturing costs are high and distribution in developing countries is challenging [11].
Most protein-based vaccine candidates, like RTS,S, which have entered clinical trials, did not
fulfill expectations [12]. Whereas RTS,S addresses the pre-erythrocytic stage of the parasite to
prevent infection, other vaccine candidates like PfAMA1 target the blood stage to reduce or pre-
vent clinical manifestation. So-called transmission-blocking vaccines that target sexual-stage
antigens and prevent transmission by the mosquito host are an essential add-on to protective or
therapeutic vaccines in the battle to eradicate malaria [13]. As a potential fourth class of malaria
vaccines anti-toxin vaccines have been proposed by Schofield et al. in 2002 [14]. A 1993 study
with a multi-stage, multi-component malaria vaccine cocktail featuring pre-erythrocytic, blood,
and sexual stage antigens yielded promising results [15] although further clinical development of
this approach was not reported. Despite the underlying complexity associated with the develop-
ment and regulatory approval of cocktails with multi-stage functionality, we believe that an opti-
mal malaria vaccine must efficiently target at least these three stages of the parasite life cycle, and
this should be the long-term goal in future malaria vaccine development as long as there is no
effective way to induce sterile immunity using pre-erythrocytic vaccine candidates.
With the aim to include several promising antigens and domains (based on previously
reported results of malaria vaccine development research) from the pre-erythrocytic, blood,
and sexual stages of the parasite in a small number of recombinant proteins, we selected 10
antigens (PfCSP_TSR [16], PfCelTos [17–19], PfTRAP_TSR [20], PfMSP1_19_EGF1 [21],
PfAMA1 [22], PfMSP4_EGF [23], PfMSP8_EGF1 and EGF2 [24], PfMSP3 [25], Pfs25 [26]
and Pfs230 [27]) and combined them in three stage-specific fusion proteins (CCT: pre-erythro-
cytic stage: PfCSP_TSR, PfCelTos and PfTRAP_TSR; E3: blood stage: PfMSP1-19_EGF1,
PfMSP4_EGF, PfMSP8_EGF1, PfMSP8_EGF2 and PfMSP3; F0: sexual stage: Pfs25 and Pfs230)
together with gAMA1 (PfAMA1, included separately to avoid an overly large fusion protein) as
one of the leading blood stage antigens, to be used as a multi-component multi-stage vaccine
cocktail called PlasmoMix. The final design of the three fusion proteins was a result of an itera-
tive expression screening approach (using the transient plant expression system) aiming to
combine previously described antigens or antigen domains in the context of a stable, well-
expressing vaccine candidate antigen. All four proteins were produced by transient expression
in Nicotiana benthamiana plants, a rapid and versatile production system that could be used
for the cost-efficient manufacture of vaccines for developing countries [28, 29].
Material and Methods
Ethics statement
Rabbits were housed, immunized and sampled by Biogenes GmbH (Berlin, Germany), accord-
ing to national animal welfare regulations. The animal facilities and protocols were reviewed
and approved by: Landesamt fμr Landwirtschaft, Lebensmittelsicherheit und Fischerei Meck-
lenburgVorpommern (LALLF M-V) (Approval No: 7221.3-2-030-13). To isolate the blood
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after immunization according to national regulations the animals were anesthetized using Ven-
tranquil, stunned using a captive bolt device and exsanguinated by throat cut.
Primary human liver cells were freshly isolated from healthy remnant material following
tumor removal surgery. The samples were received in an anonymized fashion and none of the
authors or personnel on the study was involved in the anonymization. The material was
destroyed after use in accordance with Dutch ethical legislation as described in the Medical
Research (Human Subjects) Act. The guidelines issued by the ethics committee of the Radboud
University Nijmegen Medical Center (full committee name: Commissie Mensgebonden
Onderzoek) state that no informed consent is needed for studies that use anonymised materials
and that do not reveal information that can be correlated to specific individuals or groups. The
protocol used in the current study was reviewed by the ethical committee and the waiver for
informed consent was confirmed by the committee.
Construct design and cloning
All cDNAs (Fig 1A and 1B) were obtained as N. benthamiana codon-optimized synthetic
genes from Geneart (Invitrogen, Carlsbad, CA). The four constructs were cloned as described
by Boes et al. [30] and Voepel et al. [31]. For antibody titer determination, the cDNAs coding
for the single domains were fused to the C-terminus of the fluorescent reporter protein DsRed.
The p19 silencing inhibitor gene (p19si) was modified as described [30]. All cloning steps were
confirmed by DNA sequencing.
Transient expression in N. benthamiana
The transformation and cultivation of Agrobacterium tumefaciens as well as the transient
expression in N. benthamiana plants was performed as previously described by Boes et al. [30]
and Voepel et al. [31].
Purification of antigens
Infiltrated N. benthamiana leaves were harvested 5 days post infiltration and ground in liquid
nitrogen. Purification of gAMA, F0 and CCT was performed as described by Boes et al. [30],
Beiss et al. [32] and Voepel at al. [31] respectively. E3, and all DsRed fusion proteins were puri-
fied according to the procedure described by Voepel et al. [31] with modified extraction buff-
ers. For the DsRed fusion proteins, we used PBS plus 500 mMNaCl, pH 7.4. For E3, we used
50 mM Tris-HCl pH 8 plus 500 mMNaCl.
SDS-PAGE and immunoblot analysis
Proteins were separated on 4–12% (w/v) polyacrylamide gradient gels (NuPage, Life Technolo-
gies) and either stained with Coomassie Brilliant Blue or transferred onto a nitrocellulose
membrane (Whatmann, Dassel, Germany) for immunoblot analysis as previously described by
Boes et al. [30].
Rabbit immunization, antibody titer determination and IgG purification
Three rabbits were immunized with the vaccine cocktail comprising equal amounts of the four
components formulated with a proprietary Biogenes adjuvant (an oil in water emulsion con-
taining lipopolysaccharides) on days 0, 7, 14, 28, 49 and 77, using 200 μg of antigen mix for the
prime immunization and 100 μg of antigen mix for the consecutive boosts. Serum samples
were taken on days 35 (bleed 1), 63 (bleed 2) and 91 (bleed 3). Antibody titer determination
and IgG purification was performed as previously described by Boes et al. [30].
Multi-component Multi-stage Malaria Vaccine
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Calibration free concentration analysis (CFCA)
Antigen-specific antibody concentrations were measured in the purified antibody preparations
by CFCA [33] using a Biacore T200 instrument. The four purified components (CCT, gAMA1,
E3 and F0) were individually covalently coupled to CM5-S-Series sensor chips by standard
EDC-NHS chemistry. The method is described in detail by Boes et al. [30].
Fig 1. Plant expression cassette and construct design, amino acid sequences, SDS-PAGE and immunoblot blot analysis. (A) Schematic
presentation of the expression cassettes of the plant binary expression vector pTRAk. SAR: scaffold attachment region; CaMV 35S promoter and terminator:
promoter with duplicated enhancer and terminator of theCauliflower mosaic virus (CaMV) 35S gene; 5' untranslated region: 5'-UTR of the chalcone synthase
gene from Petroselinum crispum; signal peptide sequence: transit peptide sequence of murine antibody heavy chain; GOI: Gene of interest, CCT (1), gAMA1
(2), E3 (3) and F0 (4). The restriction sites used to insert the GOI into the plant expression vector are indicated; His6 tag: six histidine affinity purification tag;
ER-retention signal: SEKDEL ER-retention signal. (B) Table containing all the information for the selected antigens. For each antigen the main stage of
expression, the name, the plasmoDB number and the amino acid sequence are depicted. SDS-PAGE (C) and immunoblot analysis (D) under reducing
conditions of the four recombinant and purified proteins. Proteins were detected using rabbit anti-His6 antiserum and alkaline phosphatase-labeled goat anti-
rabbit antiserum. M: PageRuler pre-stained protein ladder (Fermentas), lane 1: CCT, lane 2: gAMA1, lane 3: E3 and lane 4: F0.
doi:10.1371/journal.pone.0131456.g001
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Surface plasmon resonance (SPR)-based competition assay
For the reversal of growth inhibition experiments, we determined the concentrations of E3 and
gAMA1 that completely blocked the E3-specifc and gAMA1-specifc antibodies. The antigens
were buffer exchanged against RPMI 1640 (PAA, E15-041) with HEPES without L-glutamine
by repeated rounds of dilution and concentration using a VivaSpin 15R column with a MWCO
of 10 kDa. Total IgG preparations from the third bleed (day 91) were diluted to a final concen-
tration in the competition mix resulting in 40–70% inhibition in a standard growth inhibition
assay, and incubated overnight at 4°C with either gAMA1 (final concentrations 120, 12 and
1.2 μg/ml) or E3 (final concentrations 1230, 123 and 12.3 μg/ml). The competition mix was
analyzed against the corresponding antigen (E3 or gAMA1) immobilized on the CM5-S-Series
sensor chips using a Biacore T200 instrument. Full competition was defined as a RU signal less
than 5% of the sample containing no competitor.
Immunofluorescence assay (IFA)
Indirect IFAs with IgG (final concentration 1.5 μg/ml) purified from PlasmoMix-specific rabbit
immune sera were carried out using sporozoites, schizonts, macrogametes and retorts. of P. fal-
ciparum strain NF54 as previously described by Boes et al. [30].
Inhibition of sporozoite gliding motility (SGM), hepatocyte cell traversal
(HCT) and sporozoite invasion and liver stage development (SILSD)
assays
The isolation of NF54 sporozoites and their use in the gliding motility and cell traversal assays
were carried out as described by Behet et al. [34], with adaptation that for scoring the gliding
motility the number of gliding circles of 40 trails in 2 distinct wells was counted. The SILSD
assay was performed as described [35] with the following adaptations. For each well, sporozo-
ites were pre-incubated with rabbit IgG for 30 min on ice, after which the sporozoite-antibody
mixture was transferred onto the hepatocytes. On day 4 after sporozoite invasion, cells were
washed three times with PBS, fixed with 4% paraformaldehyde for 15 min at room temperature
and stained extracellular with anti-PfCSP-FITC or for the dose response experiment with anti-
PfMSP1 followed by goat anti-mouse A488 as well as intracellular with anti-PfHSP70-biotin
(StressMarq) followed by streptavidin-AF647 (Invitrogen) and 4',6-diamidino-2‐fenylindool
(DAPI). The numbers of intracellular mature parasites were determined in 20 fields by micros-
copy at 200x magnification. In the dose response experiments 16 fields at 100x magnification
(PfHSP70) or 25 fields at 200x magnification (PfMSP1) were analyzed.
In vitro growth inhibition assay (GIA)
The ability of polyclonal rabbit IgGs to inhibit the growth of P. falciparum 3D7A was deter-
mined using growth inhibition assays (GIAs) as previously described by Boes et al. [30].
Reversal of growth inhibition assay
A reversal of growth inhibition assay was used to determine the ability of antibodies directed
against either gAMA1 or E3 to inhibit parasite growth and to assess their contribution to the
overall inhibitory capacity of the immune serum. Antibodies from rabbits R1, R2 and R3 purified
from immune sera collected on day 91 were mixed with component E3 (final concentration
24 μg/ml) to completely block E3-specific antibodies. The mixture was incubated overnight at
4°C and subsequently used for a GIA as described above. The contribution of gAMA1-specific
antibodies was assessed in the same way by adding gAMA1 (final concentration 120 μg/ml) to
Multi-component Multi-stage Malaria Vaccine
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the purified antibodies. The amount needed to completely block the antibodies was determined
using the SPR-based competition experiment described above. In the absence of antigen, the
respective antibody concentration resulted in 40–70% inhibition in a standard GIA.
Antibody-dependent respiratory burst (ADRB) assay
The stimulation of human polymorphonuclear neutrophil granulocytes (PMNs) was analyzed
in ADRB assays in a total volume of 75 μl as described [36], using samples from rabbit R3_91
as example. gAMA1 or E3 (750 ng) were immobilized for the solid-phase ADRB (sADRB)
assay. Purified antibodies were adjusted to 2.5 mg/ml total IgG (comparable to the amounts
used in the reversal of growth inhibition assay). Purified IgG from normal rabbit serum (NRS)
was used at same concentration. The stimulation of 7.5 x 104 PMNs was determined by lumi-
nol-enhanced chemiluminescence.
Standard membrane feeding assay (SMFA)
Standard membrane feeding assays [37] were used to determine the ability of purified rabbit
anti-PlasmoMix antibodies to block the transmission of P. falciparum from human to mos-
quito as previously described by Feller et al. [38]. Antibodies purified from rabbit immune sera
were used at 1 mg/ml total IgG. The IC50 value was determined by analyzing purified antibod-
ies from day 91 at concentrations of 1, 0.1 and 0.01 mg/ml total IgG. Based on the CFCA
results, the total IgG concentration was converted to the F0-specific antibody concentration
and plotted against the inhibition of transmission. Statistical analysis (Mann-Whitney U) was
carried out for median numbers of oocysts between groups of mosquitoes receiving either anti-
bodies purified from normal rabbit serum (NRS) or rabbit immune sera. The oocyst prevalence
between groups of mosquitoes either receiving antibodies purified from NRS or rabbit immune
sera was statistically analyzed using Fisher’s exact test.
Results
Production of recombinant antigens
A. tumefaciens strains carrying the component expression constructs in the context of the
binary expression vector pTRA (Fig 1A and 1B) were vacuum infiltrated into N. benthamiana
plants, and subsequent purification of the recombinant antigens CCT (PfCSP_TSR, PfCelTos
and PfTRAP_TSR), gAMA1(PfAMA1), E3 (PfMSP1-19_EGF1, PfMSP4_EGF, PfMSP8_EGF1,
PfMSP8_EGF2, PfMSP3) and F0 (Pfs25, Pfs230) from crude tobacco extracts yielded highly
pure and intact proteins of the expected sizes, as shown by reducing SDS-PAGE and immuno-
blot (Fig 1C and 1D). Yields were> 1 mg/g leaf tissue for CCT and gAMA1 and> 250 μg/g
leaf tissue for E3 and F0.
Component and domain-specific antibody titers
Antibody titer analysis was performed for the cocktail (PlasmoMix), the components (CCT,
F0, E3 and gAMA1) as well as the individual recombinant domains. Antibody antibody titers
were monitored at day 0, 35, 63, and 91, and an increase of antibody titers over the sampling
period was observed for all tested antigens and domains. We recorded a antibody titer of 3.8 x
106 against the cocktail, antibody titers of 1.9–3.3 x 106 against CCT, F0 and E3, and a antibody
titer of just below 5.5 x 105 against gAMA1 (Fig 2A). For CCT, we observed a strong bias in the
antibody titers against the three pre-erythrocytic stage antigens PfCeltos, PfCSP_TSR and
PfTRAP_TSR, a antibody titer of 1.6 x 106 against the TSR-domain of PfCSP and 20-fold lower
values for the other two domains (Fig 2B). In contrast, all five blood-stage domains within E3
Multi-component Multi-stage Malaria Vaccine
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induced comparable antibody titers of approximately 4.0 x 105. A two-fold difference in anti-
body titers was observed when we compared the transmission blocking-component F0 (2 x
106) with the individual antibody titers of the two sexual-stage antigens at 4.4 x 105 for Pfs25
and 1.8 x 105 for Pfs230_C0 (Fig 2B).
Fig 2. Antigen-specific antibody titers of rabbit immune sera determined by ELISA. Three rabbits (R1, R2 and R3) were immunized six times with
PlasmoMix and serum samples were collected on days 0 (pre-immune), 35, 63 and 91. (A) The antibody titer against the immunization mixture (PlasmoMix)
as well as against the four protein-based components (CCT, E3, gAMA1 and F0) were determined. (B) To further dissect the immune response, the specific
antibody response against each individual domain was analyzed. Therefore, the domains were C-terminaly fused to DsRed (fluorescent reporter protein),
and expressed and purified as described in the methods section. Antigen domains comprising a fusion protein are connected by a bracket. Antibody titers are
shown for each rabbit (R1: open black square, R2: open red circle, R3: open blue triangle) as well as the geometric mean (black line) of three rabbits.
doi:10.1371/journal.pone.0131456.g002
Multi-component Multi-stage Malaria Vaccine
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Quantification of antigen-specific IgG responses
We performed SPR-based CFCA for the precise quantitation of the component-specific anti-
bodies in the IgG preparations purified from rabbit immune sera that were subsequently used
in in vitro inhibition assays to determine IC50 requirements for stage-specific antibody con-
centrations. Table 1 shows component-specific antibody concentration given as mg/ml as well
as % total IgG. Addintionally Plasmomix-specific IgG concentrations were calculated by add-
ing up the values obtained for the 4 components. Up to 12% (of total IgG) of Plasmomix-spe-
cific antibodies was observed for rabbit R2 in the 63 day sample.
IgG reactivity with parasite surface antigens in immunofluorescence
analysis and schizont lysate immunoblot analysis
The ability of the antigen cocktail to induce antibodies recognizing P. falciparum surface
proteins in their native context was confirmed by testing the purified IgG fractions against
parasites from different life cycle stages (sporozoites, schizonts, macrogametes and retorts) in
immunofluorescence assays. We observed strong staining localized at the surface of all P.
falciparum preparations (S1 Fig). No staining was observed for the NRS negative control. Addi-
tionally the reactivity against the native blood-stage antigens included in the context of Plas-
moMix was confirmed by immuno blot analysis using schizont lysate and purified immune
IgG from R1, R2 and R3 (Day 91). As shown in S2 Fig all Plasmodium falciparum blood-stage
proteins included within PlasmoMix could be identified based on both, molecular weight and
data reported by others: putative high molecular weight PfMSP-complex, unprocessed
PfAMA1 or PfMSP8, processed PfAMA1, PfMSP3, processed PfMSP1_42, PfMSP4 and pro-
cessed PfMSP1_19 or processed PfMSP8.
Analysis of in vitro pre-erythrocytic stage efficacy by inhibition of
sporozoite gliding motility (SGM), hepatocyte cell traversal (HCT) and
sporozoite invasion and liver stage development (SILSD)
The inhibitory efficacy of the pre-erythrocytic stage components in the context of the fusion
protein CCT was investigated using PlasmoMix-specific rabbit immune IgG in SGM, HCT
and SILSD assays. IgG samples from all three rabbits were tested in duplicate at a final
Table 1. The purified antibody preparations used for all in vitro assays. The total IgG concentrations and CFCA results are listed for each component.
Nomenclature is based on the number of the rabbit (R1, R2 or R3) followed by the sampling day (35, 63 or 91). The PlasmoMix-specific antibody concentra-
tion is the sum of the specific antibody response against the four components. The antigen-specific antibody concentration is given in mg/ml and % of total
IgG.
Sample total IgG PlasmoMix-speciﬁc-IgG CCT-speciﬁc-IgG gAMA1-speciﬁc-IgG E3-speciﬁc-IgG F0-speciﬁc-IgG
mg/ml mg/ml % total IgG mg/ml % total IgG mg/ml % total IgG mg/ml % total IgG mg/ml %total IgG
R1_35 21.70 1.23 5.65 0.40 1.85 0.41 1.87 0.16 0.76 0.26 1.18
R1_63 21.18 1.88 8.85 0.68 3.19 0.51 2.41 0.36 1.70 0.33 1.56
R1_91 19.09 1.19 6.25 0.50 2.59 0.26 1.34 0.25 1.30 0.20 1.02
R2_35 22.60 1.72 7.63 0.31 1.35 0.75 3.32 0.38 1.69 0.29 1.26
R2_63 17.08 2.17 12.69 0.50 2.90 0.84 4.92 0.47 2.77 0.36 2.11
R2_91 22.25 2.34 10.52 0.63 2.83 0.78 3.51 0.54 2.43 0.39 1.75
R3_35 27.40 2.24 8.17 0.31 1.13 0.80 2.90 0.52 1.89 0.62 2.25
R3_63 23.13 1.46 6.30 0.28 1.21 0.51 2.20 0.29 1.26 0.38 1.62
R3_91 25.03 1.95 7.79 0.54 2.16 0.62 2.46 0.41 1.62 0.39 1.56
doi:10.1371/journal.pone.0131456.t001
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concentration of 3 mg/ml and we observed up to 48% inhibition of SGM, 34% inhibition of
HCT and 81% inhibition of SILSD (Fig 3). Further, IC50 values for the inhibition of SILSD
Fig 3. In vitro inhibition of (A) sporozoite glidingmotility, (B) hepatocyte cell traversal, (C) sporozoite invasion and liver stage development with
PlasmoMix-specific rabbit IgG and (D) Dose response of sporozoite invasion and liver stage development. All three assays were performed with P.
falciparumNF54 parasites and purified rabbit IgGs (R1, R2 and R3) at a total IgG concentration of 3 mg/ml from serum samples collected on days 63 and 91.
For the dose response, purified rabbit IgGs from rabbit R3 (day 63 and day 91) was used at the following total IgG concentrations: 9, 3, 0.9 and 0.09 mg/ml.
The CCT-specific antibody concentration was calculated based on CFCA from total IgG. Inhibitions are expressed as the mean of duplicate measurements
with standard deviations.
doi:10.1371/journal.pone.0131456.g003
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were determined in a dose response experiment using purified immune IgG from rabbit R3 at
day 63 and 91 (R3_63: 25.5 μg/ml and R3_91: 17.1 μg/ml).
Analysis of in vitro blood stage efficacy by growth inhibition assay (GIA)
The efficacy of the blood-stage component of the vaccine cocktail (antigens gAMA1 and E3)
was assessed using a classical GIA. Up to 90% inhibition was observed at a concentration of 6
mg/ml total IgG purified from rabbit immune sera (Fig 4A). Determination and comparison of
IC50 values for antigen-specific IgGs indicated that the IC50 values for gAMA1-specific anti-
bodies (Fig 4B) were in the same range (30–60 μg/ml) as reported in a previous study [30] after
the immunization of rabbits with recombinant plant-derived gAMA1, indicating that the
growth inhibition induced by the cocktail is mainly mediated by gAMA1-specific antibodies.
To precisely quantify this contribution, a reversal of growth inhibition assay was performed by
competitive neutralization of these antibodies with recombinant gAMA1 and E3 (Fig 5).
Although growth inhibition was completely abolished by 120 μg/ml gAMA1, the neutralization
of E3-specific IgGs using 24 μg/ml E3 did not affect growth inhibition.
Analysis of in vitro sexual stage efficacy by standard membrane feeding
assay (SMFA)
The SMFA was used to investigate the transmission-blocking efficacy of the sexual stage-spe-
cific component F0 (Pfs25 and Pfs230_CO). The observed transmission-blocking activity
(reduction in oocyst formation) of 95–100% for the samples from the three animals for all
three bleeds (S1 Table) demonstrated the potency of the F0 fusion antigen comprising Pfs25
and Pfs230_CO, agreeing with previous reports based on these antigens [15, 27, 39]. The
amounts of F0-specific antibodies measured in the samples taken at day 91 by SPR-based
CFCA analysis were correlated with a corresponding dose response TBA, revealing an IC50
value of< 2 μg/ml (Fig 6).
Discussion
A cocktail featuring key antigens from different stages of the P. falciparum life cycle is a prom-
ising approach for malaria vaccine development. We therefore investigated the antibody
responses generated by immunizing rabbits with an equal mixture of four different recombi-
nant proteins featuring suitable antigens from the pre-erythrocytic (PfCSP_TSR, PfCelTos
and PfTRAP_TSR), blood (PfAMA1, PfMSP1-19_EGF1, PfMSP4_EGF, PfMSP8_EGF1,
PfMSP8_EGF2 and PfMSP3), and sexual stages (Pfs25 and Pfs230) of P. falciparum. The four
recombinant proteins were successfully produced by transient expression in N. benthamiana
plants. Yields of 0.25–1.0 mg per g fresh leaf weight were comparable to typical expression lev-
els achieved using this system [40, 41] and the fact that intact and highly pure proteins could
be isolated indicated that all four vaccine antigens are suitable for production in the plant tran-
sient expression system.
The analysis of PlasmoMix-specific rabbit immune sera obtained using a hyperimmuni-
zation protocol that aims for maximum antibody titers revealed differences in reactivities
against the different antigen domains with antibody titers ranging from 7.7 x 104 (PfCeltos and
PfTRAP) to 1.6 x 106 (PfCSP-TSR). The observed antibody titer bias between fused domains as
observed for CCT and F0 agrees with our previously observed data based on corresponding
mouse immune sera [31, 32]. The gAMA1-specific antibody titers were 2–3 times lower than
we previously observed for gAMA1-specific rabbit immune sera, where 3.5 times more antigen
was used [30]. The antibody titers of the domains within the E3 component were balanced at
3.5 x 105. Immunofluorescence analysis confirmed the reactivity of the PlasmoMix-specific
Multi-component Multi-stage Malaria Vaccine
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immune sera against all the tested P. falciparum stages, and the staining patterns were in accor-
dance with the results of previous studies by our group and others [30, 31, 39, 41–43] after
immunization with the same or comparable antigens. Typical PfAMA1-specific apical staining
of merozoites could not be observed, since many other non-localized merozoitze surface
proteins were stained in parallel. To further confirm the reactivity against all individual
Fig 4. In vitro growth inhibition assay (GIA) of asexual P. falciparum 3D7 parasites with purified PlasmoMix-specific rabbit IgG. The rabbit IgGs were
purified from the serum of three rabbits (R1, R2 and R3) collected on days 35, 63 and 91 post-immunization with PlasmoMix. Nomenclature of the sample first
features the number of the rabbit (R1, R2 or R3) followed by the sampling day (35, 63 or 91). (A) Four serial 1/1 dilutions from 6–0.75 mg/ml of total IgGs were
used to demonstrate the concentration dependency of the assay and to calculate the IC50 values (the total IgG concentrations needed for 50% inhibition). (B)
The same GIA but instead of total IgG, the gAMA1-specifc antibody concentration (based on CFCA and calculated from total IgG, see methods section) was
used and the IC50 values for gAMA1-specific antibodies were calculated. Each data point represents the mean of technical triplicates.
doi:10.1371/journal.pone.0131456.g004
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blood-stage antigen included in PlasmoMix a schizont lysate immunoblot was performed with
purified PlasmoMix-specific rabbit immune IgG. The detected bands were identified by appar-
ent molecular weight in comparison with the following studies performed on the respective
Plasmodium falciparum proteins [44–48].
For ethical reasons and because of these preexisting results for single antigen vaccination
experiments with three of the PlasmoMix components we did not perform single antigen vacci-
nations for all the four components along with the PlasmoMix experiments. In this context it
should be noted that this initial study to investigate a multistage vaccine cocktail was not
Fig 5. Reversal of growth inhibition assay. The assays were performed with P. falciparum 3D7 parasites and with the intention to assess the inhibitory
potential of antibodies directed against either gAMA1 or E3. The GIA was run with purified antibodies from serum samples taken on day 91 post-
immunization with PlasmoMix. The assay was carried out with a total IgG concentration resulting in 40–70% inhibition in a standard GIA in the presence of
either gAMA1 (A) or E3 (B) to reverse the inhibition. Each data point represents the mean with standard deviation of technical triplicates.
doi:10.1371/journal.pone.0131456.g005
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performed with a human compatible adjuvant or vaccination regime and that conclusions
regarding the effect of such a cocktail under different conditions have to be further
investigated.
Stage-specific inhibition assays were used to address the in vitro efficacy of PlasmoMix. The
three pre-erythrocytic stage assays showed promising inhibition values between 34% for hepa-
tocyte cell traversal and 81% for hepatocyte invasion and maturation. These values are high
compared to our previous results using CCT in a mouse immunization study, which achieved a
reduction of only 35% in a hepatocyte invasion assay [31]. However these results were obtained
using the immortalized liver cell line HepG2 rather than the human primary hepatocytes used
in this study. R3 is the only rabbit that showed a correlation between the concentration of
CCT-specific IgG and the percentage effect in both the HCT and SILSD assays, but not the
SGM assay, over time. There was no link between overall CCT IgG-specific antibodies and
specificity, which might indicate that each rabbit produces different amounts of functional
IgG. Clear inhibition in pre-erythrocytic in vitro assays has been reported for the single anti-
gens PfCSP_TSR and PfCeltos in previous studies [19, 49], whereas the results for PfTRAP are
contradictory [20, 50]. Antibodies against PfCSP play a role in gliding motility [51], whereas
PfCeltos-specific antibodies interfere with cell traversal and have another mode of action affect-
ing not only sporozoites at the site of infection but also intra-hepatocyte parasites [52]. We
believe that the inhibition observed in the three different assays could be a cumulative effect of
all three antigens and further studies are needed to dissect the contribution of each antigen.
The IC50 values determined for the rabbit R3 (R3_63 & R3_91) were in the lower μg/ml range
(17.1–25.5 μg/ml) and therefore in between the IC50 value observed for the sexual-stage and
blood-stage specific inhibition assays (see below). It is difficult to compare the IC50 value with
data from other studies, because most of them use ELISA units (EU) or arbitrary units (AU)
instead of absolute concentrations of antigen-specific IgG as we have determined by CFCA in
Fig 6. Correlation of transmission blocking activity and F0-specific antibody concentration. The rabbit
IgGs were purified from serum samples collected on day 91 post-immunization with PlasmoMix. To demonstrate
the concentration dependency of the transmission blocking activity, the TBA was performedwith purified
antibodies from each rabbit (R1: black, R2: open and R3: hatched) at total IgG concentrations of 1 mg/ml
(circles), 0.1 mg/ml (squares) and 0.01mg/ml (triangles). Based on the CFCA results, the F0-specific antibody
concentration was calculated, plotted and used to determine the IC50 value (the antibody concentration needed
to obtain 50% inhibition of transmission). For detailed results of the transmission blocking assay, refer to S2
Table.
doi:10.1371/journal.pone.0131456.g006
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this study. Estimations on protective levels of PfCSP-specific antibodies derived from immuni-
zation studies with RTS,S suggest concentrations of> 20μg/ml [53].
Up to 90% inhibition was observed in the GIA with 6 mg/ml total IgG. Surprisingly, as
shown by the reversal of growth inhibition, the activity in this experimental context was exclu-
sively mediated by anti-PfAMA1 antibodies. This conclusion is also supported by the IC50 val-
ues for gAMA1-specific antibodies, which provide no evidence for a synergistic or additive
effect of E3-specific antibodies in this GIA when compared to similar values induced by
gAMA1 alone [30]. At least PfMSP1-19-specific antibodies play a role in naturally acquired
immunity [54] and immunization with recombinant PfMSP1-19 can induce growth inhibitory
antibodies [55] even though it is known that PfAMA1 is more immunogenic and causes stron-
ger growth inhibition than PfMSP1-19 [56]. Faber et al. [8] demonstrated a small but signifi-
cant contribution of PfMsp1-19-specific antibodies induced by immunization with
PfAMA1-DICO_PfMsp1-19 fusion proteins. In this study, an IC50 of>200 μg/ml PfMsp1-19
specific antibodies (affinity purified from rabbit immune IgG) was determined, leading us to
the conclusion that the lacking effect of E3-specific and/or PfMsp1-19-specific IgGs might be
explained by the much lower concentrations of these antibodies (<50 μg/ml for E3 and, look-
ing at the antibody titer ratios, most probably less than 10 μg/ml for PfMSP1-19) induced by
the immunization with PlasmoMix. Our GIA data for blood-stage malaria vaccine candidate
efficacy highlight the role of PfAMA1 as a leading blood-stage antigen. Nevertheless, we
included the fusion protein E3 to provide additional promising blood-stage antigens such as
PfMSP3 and PfMSP1-19, which have been associated with antibody-dependent cell-mediated
immunity (ADCI) [24,48], to diversify the blood-stage efficacy of the vaccine cocktail, even
though we did not perform ADCI assays in the context of this work. Antibody-dependent
respiratory burst assay (ADRB) is another method to address parasite-neutralizing activity of
antibody preparations using human polymorphonuclear neutrophil granulocytes (PMN) as
effector cells [36]. In the context of this work we conducted an initial experiment that demon-
strates for the first time that rabbit antibodies can stimulate human PMNs (S3 Fig). We con-
firmed that gAMA1 as well E3-specific rabbit immune IgG are capable of inducing respiratory
burst in a direct coating assay. In future studies we will develop and implement these assays to
analyze ADRB activity of rabbit immune IgG on parasites.
Besides the theoretical ability to generate broadly-neutralizing immune responses, the use of
cocktails containing several recombinant antigens bears the risk of diluting the response and
losing efficacy by antigenic competition. In the context of PlasmoMix, we can address this
hypothesis by combining the data reported herein with our previous results obtained after the
immunization of rabbits with PfgAMA1 [30]. While overall antibody titers directly correlated
with the amounts of gAMA1 used in the PlasmoMix or gAMA1 immunizations, the inhibitory
quality of the induced antibodies was not affected (similar IC50 values for the gAMA1-specific
IgG). Anyhow in the cocktail a significant increase of the IC50 value for total IgG and thus a
lower GIA efficacy was observed. Even though we did not generate comparable data for the
remaining three PlasmoMix components we are convinced that antigenic competition plays a
significant role in responses to multi-antigen cocktails. Although based on an observation with
just one cocktail, this finding should be taken as a serious message that antigens within vaccine
cocktails must be chosen carefully, and their number should be kept as low as possible to avoid
the observed dilution of essential inhibitory antibodies.
The 100% reduction of oocyst formation observed in the sexual stage transmission blocking
assay is in agreement with our own data from mouse immunizations with F0 [32] and results
from previous studies with different variants of Pfs25 [26, 39, 40, 57] or Pfs230 [27, 41, 42].
The determined IC50 value (<2 μg/ml) is below, but in the same range as the one reported by
([58], 4.2μg/,ml) using Pfs25-specific rabbit immune IgG. The observed IC50 value may derive
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from both, Pfs25 and Pfs230_C0-specific IgG, anyhow the lack of replicates does not allow the
conclusion that an additional contribution of Pfs230_C0-specific antibodies is the reason for
the two fold lower value. Therefore it will be necessary to dissect and quantify the contribution
of each of the sexual-stage antigens (Pfs25 and Pfs230_C0) in additional experiments to opti-
mize the next generation of the PlasmoMix vaccine cocktail. The results also indicate that, at
least in rabbits, it should be possible to reduce the amount of this component within the vac-
cine cocktail without compromising transmission-blocking efficacy, thus allowing other com-
ponents to be over-represented and to induce higher antibody antibody titers for optimal
protection against other (pre-erythrocytic and blood) stages.
Conclusions
Our data suggest that cocktails comprising different stage-specific components remain a prom-
ising approach for the development of a malaria vaccine. However, our results also indicate the
different components should not be mixed in equal amounts but in optimal ratios to generate
what may be called “balanced efficacy”. The fine tuning of a new vaccine cocktail containing
the PlasmoMix antigens may require: (1) the removal of some antigens; and (2) the adjustment
of the relative concentrations of the remaining to compensate for the observed different IC50
requirements and at the same time taken into account the role of the respective stage in the
context of the establishment and the clinical manifestation of the disease.
Supporting Information
S1 Fig. Immunofluorescence assay of NF54 parasites in different stages. For IFAs, P. falcipa-
rum NF54 parasites in the sporozoite, schizont, macrogamete and retort stages were fixed with
methanol on the surface of a slide. Exemplary shown is the detection with purified IgGs from
rabbit R2 from the serum sample collected on day 91 after immunization with PlasmoMix. As
positive controls, murine antisera against PfCSP (sporozoite), PfMSP1-19 (schizonts), Pfs25
(magrogametes) and Pfs28 (retorts) were used, respectively. Rabbit antibodies were visualized
with anti-rabbit secondary antibody labeled with Alexa Fluor 594 (red) while visualization of
murine antibodies was performed with secondary Alexa Fluor 488 labeled anti-murine anti-
body (green). Parasite nulcei were highlighted with Hoechst 33342 (blue). Transm: Transmis-
sion light. Bar: 5 μm.
(TIF)
S2 Fig. Schizont lysate immunoblot analysis. Purified rabbit immune IgG (R1, R2 and R3
from day 91) were used to detect native Plasmodium falciparum blood-stage antigens in immu-
noblot analysis with schizont lysate. 12 μl lysate (corresponding to 1.5x107 schizonts) were sep-
arated under non-reducing conditions by SDS-PAGE. After immunoblot the membrane was
blocked with skimmed milk and probed with rabbit immune IgG adjusted to 5 μg/ml PfA-
MA1-spacific IgG concentration. Bound rabbit antibodies were detected with an alkaline phos-
phatase goat anti-rabbit serum. Antibodies purified from normal rabbit serum (NRS) were
used as negative control.
(TIF)
S3 Fig. Antibody-dependent respiratory burst assay.Human polymorphonuclear neutrophil
granulocyte (PMN) responses towards purified PlasmoMix-specific rabbit immune IgG. Sam-
ple (R3_91, black squares) was analyzed using ADRB on coated antigens gAMA1 (A) and E3
(B) over a 60 min kinetic window with PNMs from one donor. Antibodies purified from nor-
mal rabbit serum (NRS) were used as negative control (red circles).
(TIF)
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S1 Table. Evaluation of transmission blocking activity of purified rabbit IgGs. Rabbit (R1,
R2 and R3) were immunized with PlasmoMix and antibodies were purified from serum sam-
ples collected on days 35, 63 and 91. Polyclonal rabbit antibodies were used at a total IgG con-
centration of 1 mg/ml and based on the CFCA results, the F0-specific antibody concentration
was calculated and listed. Antibodies purified from normal rabbit sera (NRS) was used as a
negative control. Samples from day 63 and 91 were run in the same assay and refer to the same
NRS, listed above R1_63. (a) We used a Mann-Whitney U test to analyze the median numbers
of oocysts during infection with P. falciparum between groups of mosquitoes receiving either
antibodies purified from NRS or purified from rabbits immunized with PlasmoMix. P-values
below 0.05 were considered significant. (b) The prevalence of oocysts during the infection with
P. falciparum between groups of mosquitoes receiving either antibodies purified from NRS or
antibodies purified from rabbits immunized with PlasmoMix was analyzed using the Fisher’s
exact test. P-values below 0.05 were considered significant.
(DOCX)
S2 Table. Correlation of transmission blocking activity and F0-specific antibody concentra-
tion. Antibodies were purified from serum samples collected on day 91 after immunization
with PlasmoMix and used at total IgG concentration of 1 mg/ml, 0.1 mg/ml and 0.01 mg/ml.
The F0-specific antibody concentration was calculated based on the CFCA experiment. Anti-
bodies purified from normal rabbit sera (NRS) was used as a negative control. Statistical analy-
sis was performed as described in S1 Table.
(DOCX)
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